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Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A 
Comparative Review of International Regulations 
Abstract 
Cell and tissue-based products, such as autologous adult stem cells, are being prescribed by 
physicians across the world for diseases and illnesses that they have neither been approved 
for or been demonstrated as safe and effective in formal clinical trials. These doctors often 
form part of informal transnational networks that exploit differences and similarities in the 
regulatory systems across geographical contexts. In this paper, we examine the regulatory 
infrastructure of five geographically diverse but socio-economically comparable countries 
with the aim of identifying similarities and differences in how these products are regulated 
and governed within clinical contexts. We find that while there are many subtle technical 
differences in how these regulations are implemented, they are sufficiently similar that it is 
difficult to explain why these practices appear more prevalent in some countries and not in 
others. We conclude with suggestions for how international governance frameworks might be 
improved to discourage the exploitation of vulnerable patient populations while enabling 
innovation in the clinical application of cellular therapies. 
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Introduction 
Over the last decade, the use of human cell and tissue-based products (CTPs) in new and 
innovative therapies has drawn increasing interest from healthcare providers, researchers, 
patients, and regulators, internationally. However, despite there being few accepted clinical 
uses (Daley 2012), CTPs are increasingly being prescribed for conditions that have not been 
demonstrated as safe or effective in clinical trials. In particular, autologous adult stem cells 
(ASCs) are being offered directly to patients, typically over the Internet, for a wide range of 
diseases and conditions for which there is insufficient evidence that demonstrates their safety 
and efficacy (Regenberg et al. 2009, Lau et al. 2008). While evidence has emerged in recent 
years to reduce initial safety fears about the tumour-forming properties of ASCs, clinical data 
that supports the efficacy of these products for many indications has been either limited to 
early Phase I/II trials, or in some cases, non-existent (Power and Rasko 2011).  
Until recently, these practices were utilized mainly by patients travelling from wealthy 
nations to low-to-middle income countries, or so-called ‘stem cell tourism’ (c.f. Lysaght and 
Sipp 2015). These countries, including China, Thailand, and India (Regenberg et al. 2009, 
Lau et al. 2008), were assumed to foster stem cell clinics because they lacked the necessary 
regulatory infrastructure to monitor and control the practices of clinics and healthcare 
institutions operating within their jurisdiction (Kiatpongsan and Sipp 2008). This picture is, 
however, no longer adequate, as autologous ASCs are increasingly being offered in wealthy 
countries, such as the United States (Turner and Knoepfler 2016), Japan (Fujita et al. 2015) 
and Australia (McLean, Stewart, and Kerridge 2014). The emergence of these domestic 
markets means that patients need no longer travel long distances to access ‘unproven’ cellular 
therapies, and that the global escalation of these practices cannot be simply explained as a 
matter of weak or absent regulation in emerging economies. 
In a study funded by the Economic and Social Research Council in the United Kingdom, 
Petra and Sleeboom-Falkner (2009) describe how disparities in regulatory systems across 
geographical contexts are being exploited by what they term as ‘bionetworks’. These 
networks are represented by loosely organized transnational relationships between 
physicians, science entrepreneurs, researchers and patients, who operate mostly, although not 
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exclusively, within the private healthcare sector (Sleeboom-Faulkner and Patra 2011). They 
work in part by exploiting differences and inequalities in the provision of healthcare, 
standards of wealth, capacity to conduct scientific research, and regulatory infrastructure 
between rich and poor(er) countries. While this study provides some evidence of bionetworks 
extending out of Asia and into the protected markets of the so-called ‘West’, most notably 
through patient recruitment (Patra and Sleeboom-Faulkner 2009), their infiltration into high 
income countries with lucrative domestic markets for novel therapeutics has not been uniform 
nor has it been essential for the global proliferation of clinics offering autologous ASCs 
outside clinical trials.  
The global reach of bionetworks is most clearly visible in the recent events in Texas, where 
the Governor Rick Perry was administered with autologous ASCs processed using 
technology imported from the Seoul-based company K-STEMCELL, formerly operating as 
RNL Bio (Lysaght et al. 2013). This intervention followed a similar procedure that had been 
carried out on Perry’s treating physician at a clinic associated with RNL Bio in Japan 
(Berfield 2013), one of a number of clinics are purportedly offering autologous ASCs (Fujita 
et al. 2015). Yet, in Australia, where a sharp increase in such clinics has occurred following 
the introduction of a new regulatory framework for CTPs (McLean, Stewart, and Kerridge 
2014, Munsie and Pera 2014), the connections with bionetworks in Asia or elsewhere are less 
visible. Furthermore, other countries such as Singapore, Canada and the United Kingdom, 
have been relatively successful in controlling the use of autologous ASCs within their 
borders. Hence, there could be differences in regulatory systems between  wealthy nations 
with similar standards in healthcare, scientific investment and economic structure that may be 
influencing the provision of autologous ASCs to patients outside clinical trials.  
This paper examines the regulatory systems of five geographically diverse but socio-
economically comparable countries with the aim of identifying similarities and differences in 
how novel uses of CTPs are regulated and governed within clinical contexts. We follow this 
examination with a discussion about the strengths and weaknesses of these approaches and 
suggest ways in which international governance may better achieve a balance between the 
need to protect vulnerable patient populations and the desire to enable scientific and clinical 
innovation. Specifically, we argue for greater consistency and clarity in regulatory 
4 
 
instruments across jurisdictions and encourage the relevant authorities within the medical 
profession to take a greater leadership role in sanctioning unethical and irresponsible 
practices with CTPs.   
Comparative Review of International Regulatory Approaches to CTPs 
The five countries selected for the comparative review – Australia, Japan, Singapore, the UK, 
and the USA – were chosen from the extant literature because of their comparability across 
key socioeconomic and health indicators. They are all structured as capital markets and are 
among the 46 countries classified by the World Bank as high-income economies (World 
Bank 2012). They each spend between 1.7 and 3.4% of gross domestic product a year in 
research and development (World Bank 2008) and have comparably high capacities for 
scientific research (IMD 2013). While different healthcare systems are in place, the standards 
of healthcare offered to patients are relatively stable across these jurisdictions. These 
countries have also invested heavily in biomedicine and medical biotechnologies, including 
regenerative medicines based on stem cells and other CTPs. 
To support this investment, these countries have all established regulatory infrastructure to 
enable the protection of intellectual property rights and govern research involving human 
subjects. Regulations for human subject research in each country are based on internationally 
accepted norms initially set in the Nuremberg Code and later adopted by the World Medical 
Association (WMA) in the Declaration of Helsinki and the Council for International 
Organizations of Medical Sciences (CIOMS) for the International Ethical Guidelines for 
Biomedical Research Involving Human Subjects. These norms include imperatives for 
informed consent, privacy, confidentiality, and independent oversight from an Institutional 
Review Board (IRB) or an equivalent body. Most of these countries have also established 
extensive frameworks for research involving human stem cells and tissues.  
While the five jurisdictions employ different regulatory mechanisms to control the use of 
human embryos in research, they all generally provide relatively permissive environments for 
stem cell research (Chalmers 2010). All countries, except the USA, have specific legislation 
that prohibits the use of human cloning techniques for reproductive purposes and all five 
jurisdictions have regulations that allow research on human embryonic stem cells (ESC). In 
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addition, all countries have established regulatory frameworks for the sale of medicinal drugs 
and governance of medical practice. As the following analysis indicates, there are technical 
differences in how these regulations are implemented. However, there are also broad 
similarities with the general approach taken in each jurisdiction that do not lead to simple 
explanations as to why the use of autologous ASCs appears more prevalent in some countries 
and not others. In the following, we describe these regulations and provide some critical 
commentary focusing on provisions specific to autologous uses of ASCs within both formal 
clinical trials and the practice of medicine. 
United States 
In the USA, the Food and Drug Administration (FDA) has jurisdiction over medicinal drugs, 
devices and biologics that are entered into interstate commerce; meaning that products (or 
products composed of ingredients) that are shipped interstate fall under the federal regulatory 
authority (FDA 1978). The FDA controls market entry of these products through 
requirements for premarket testing of safety and efficacy in specified indications, which 
usually involves a series of registered multiphase (I–III) clinical trials that are conducted after 
the sponsor obtains an Investigational New Drug (IND) designation. Subsequent market 
authorisation may include additional requirements for post-market surveillance.  
Regulation of CTPs is administered by the Center for Biologics Evaluation and Research 
(CBER) Office of Cellular, Tissue, and Gene Therapies (OCTGT) within the FDA, and 
depending on their specific formulation, may be classified as devices, drugs, and/or biologics. 
CTPs are then subdivided according to criteria set out in the Code of Federal Regulations 
(CFR) that are intended to establish whether the product is: 1) more than minimally 
manipulated 2) intended for non-homologous use; 3) combined with other articles; or, 4) if 
not for autologous use, either exerts systemic effects or relies on metabolic activity. If a CTP 
meets any of these definitions, it is categorized under section 351 of the Public Health 
Services (PHS) Act (1944) and regulated as a biological drug according to the CFR as a “351 
product”. This categorisation requires pre-market authorisation from CBER and compliance 
with Good Manufacturing Practices (GMPs). However, CTPs that do not meet any of these 
definitions are regulated solely under Section 361 of the PHS Act as “361 products”, which 
do not require the pre-market evaluation required for 351 products.  
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While the processing of 361 products should comply with Current Good Tissue Practice 
(CGTP) standards intended to prevent contamination by the spread of communicable diseases 
(CBER, 2011), their use within clinical contexts, along with ‘off-label’ uses of approved 351 
products, constitutes a medical procedure that lies outside the FDA’s jurisdiction. Medical 
procedures are instead governed within the practice of medicine by medical boards and civil 
statutes in each of the 50 American states. In 2012, the Texas Medical Board (2012) 
introduced rules on the investigational use of human stem cells that appears to provide an 
alternative to the IND pathway by allowing physicians to seek IRB approval to prescribe 
agents not approved by the FDA in their practice.  Despite these rules, federal laws pertaining 
to manufacturing standards supersede state laws and they are unlikely to provide protection 
against legal action taken by the FDA in asserting its authority over CTPs that fall within its 
jurisdiction.   
Indeed, the FDA has exerted its authority over the manufacturing of autologous ASCs 
processed on-site for non-homologous uses in the District Court of Columbia. This court 
broadly upheld the FDA’s interpretation of CTPs that are entered into interstate commence as 
defined in CFR 1271 (see US Court of Appeals 2014). The FDA has also issued a warning 
letter to a storage facility in Texas over violations of GMP standards for adipose-derived stem 
cells. In addition, the Federal Bureau of Investigation successfully prosecuted the owner of 
laboratory in Arizona for unlawfully introducing allogeneic cord blood cells into interstate 
commerce while investigations into other related cases of mail fraud involving stem cells 
continue (Callaway 2011). Civil action has also been initiated against the American 
subsidiary of RNL Bio, RNL Biostar, for allegedly providing misleading information about 
the efficacy of their autologous ASC product (Cyranoski 2012). The outcomes of these 
lawsuits, and their impact on the availability of ASCs outside clinical trials, remain to be 
seen.  
The USA faces many difficulties in controlling the number of clinics offering putative stem 
cell treatments, not least because of a federal system that has generated a patchwork of state-
based regulations for the governance of medical practice. This system allows physicians who 
are notified by regulatory authorities to cease and desist in one state, to easily move into 
another where they hold medical licensure, or partner with other physicians who are 
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registered to practice in that state.  They can also relocate the clinic to another country, such 
as Mexico, where they can evade regulatory oversight while marketing the interventions to 
American patients (Turner 2015). Exacerbating this situation are the ambiguities in the FDA 
regulations on what constitutes ‘no more than minimal manipulation’, which is defined in 21 
CFR 1271.3(f)(2) simply as “processing that does not alter the relevant biological 
characteristics of cells”. Rather than specifying techniques or processes that would count as 
minimal manipulation, or not, this definition relies on what impacts the processing has on the 
integrity of the cells or tissues from their original state. This vagueness is open to 
interpretation and may have encouraged the introduction of invented techniques, such as 
‘stromal vascular centrifugation’ of adipose-derived stem cells. While new Draft Guidelines 
for HCT/Ps from adipose tissues may help to clarify these definitions (FDA 2014), without 
specifying the techniques that constitute minimal manipulation, they may still leave open the 
opportunity for clinics to circumvent the regulations.  
Japan 
Japan has a pre-market evaluation process for drugs and devices that is similar to the FDA 
system where market approval is generally provided following the evaluation of data from 
clinical trials that demonstrates safety and efficacy. Clinical trial data is reviewed by the 
Pharmaceuticals and Medical Device Agency (PMDA) – an administrative agency 
established under the Ministry of Health, Labour and Welfare (MHLW) under powers 
conferred by the Pharmaceutical Affairs Law (PAL)..In practice, requests and notifications 
are generally submitted to the PMDA, which reviews the submission and reports its opinion 
to MHLW, which either grants marketing approval or makes further recommendations.  
In May 2013, the Japanese Diet introduced widespread changes to this legislative framework 
with the enactment of the Regenerative Medicine Promotion Law (2013). The new legislative 
framework includes amendments to the PAL, which has been renamed as the 
Pharmaceuticals and Medical Devices and Other Therapeutic Products Act (PMD Act), and 
the introduction of the Act on the Safety of Regenerative Medicines (ASRM 2014) as well as a 
slew of administrative guidance documents, ministerial ordinances, and guidelines on product 
quality, safety and efficacy (Azuma 2015). This framework was introduced, in part, to speed-
up the approval process for new regenerative medicine products, particularly induced 
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pluripotent stem (iPS) cells that were first developed in Kyoto; but also in response to the 
country’s growing reputation as a destination for medical tourists seeking out unproven stem 
cell-based interventions (Konomi et al. 2015). 
Prior to these changes, CTPs were not explicitly regulated under the PAL unless they could 
be classified as drugs or devices according to their mode of action (Azuma 2015). However, 
this only included processed CTPs that were expanded ex-vivo, treated pharmacologically for 
activation, biologically-altered, combined with scaffolds or genetically modified; 
unprocessed CTPs1 were excluded and their use presumably fell within the practice of 
medicine, which is regulated by the Medical Practitioners Law (MPL) (1948). This law, 
which the MHLW also administers, considers a practitioners’ act of producing an unapproved 
drug and administering it to a patient as falling within the scope of ‘physician discretion’ in 
medical practice. CTPs administered in this context thus were not governed by the PAL and 
practitioners did not need to seek prior approval from the MHLW/PMDA when acting within 
this zone of discretion. If the CTP was administered in the context of clinical research, as 
distinguished from a clinical trial (chiken), then practitioners were expected only to observe 
the 2003 Ethical Guideline on Clinical Research, and the Guidelines on Clinical Research 
Using Human Stem Cells (2006 Guidelines) if stem cells were used.  
With the new laws, companies aiming to evaluate the safety and efficacy of CTPs for market 
distribution in clinical trials will be regulated under the PMD Act, while institutions that use 
stem cells in clinical research or medical practice will fall under the ASRM (Azuma 2015). 
The PMD Act provides sponsors of clinical trials with a conditional and time-limited 
approval to market CTPs once safety and probable benefit has been demonstrated in early 
clinical studies (Konomi et al. 2015). Sponsors will then have a maximum of seven years to 
submit data from post-marketing trials to evaluate efficacy and may apply to the national 
insurance scheme for reimbursement, subject to the approval of the Central Social Insurance 
Medical Council. CTPs that are provided under the ASRM must be processed in a licensed 
facility for quality assurance and reviewed according to a three-tiered risk-based 
                                                 
1 Includes the separation of tissue, mincing of tissue, separation of cells, isolation of specified cells, treatment by 
antibiotics, rinsing, sterilisation by gamma-rays etc., freezing and thawing. See Guidelines on Ensuring Quality 
and Safety of Products Derived from Processed Cell/Tissue (PFSB/MHLW ) Notifications, 2008.  
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classification system (i.e. low, medium or high) that is overseen by committees certified to 
approve the use of these products in medical practice and clinical research. Companies will 
be permitted to use data from clinical research conducted at medical institutions to 
demonstrate product safety under the PMD Act.  
While it may be too soon to predict the full implications of this framework, early indications 
suggest that businesses and industry are manoeuvring to exploit the new laws. In September 
2015, the MHLW authorised the first conditional approval under the PMD Act for an 
autologous cell product for use in patients with serious heart failure on the basis of evidence 
submitted from a single small-scale (n = 7) open-label clinical trial (Sawa et al. 2015).  In 
addition to the approval, the Central Social Insurance Medical Council set a price of 
approximately $122,000 USD for a standard course, which has shifted investment risks from 
the developer to the Japanese taxpayer and patients who still contribute a 30% co-payment 
for an under-tested product with uncertain safety and efficacy (McCabe and Sipp 2016). 
Moreover, the ASRM is likely to encourage clinics to continue marketing autologous ASCs 
with a highly decentralised oversight model that places the responsibility of classifying CTPs 
with certified committees that interpret the regulations and determine a product’s level of risk 
based on guidance documents that lack enforcement in law (Lysaght and Sugii 2016). With 
more than 128 committees currently certified with the regulator, there is much room for 
variation in how this guidance is interpreted and applied to specific products.  
Australia 
In Australia, CTPs are regulated federally by the Therapeutic Goods Administration (TGA) 
under the Therapeutic Goods Act (1989) according to the framework for biologicals (Trickett 
and Wall 2011). This framework categorises CTPs as either being: 1) regulated as therapeutic 
goods, but not as biological goods; 2) regulated as biological goods under the biologicals 
framework; and 3) not regulated as biological goods (excluded from regulation).2 The first 
category includes biological prescription medicines, such as vaccines, blood, plasma 
                                                 
2 Part 3-2A of the Therapeutic Goods Act 1989 defines biologics as“a thing made from, or that contains, human 
cells or human tissues and that is used to treat or prevent disease, ailment, defect or injury; diagnose a condition 
of a person; alter the physiological processes of a person; test the susceptibility of a person to disease; or replace 
or modify a person’s  body parts”  
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derivatives, and cryopreserved haematopoietic progenitor cells that are used for 
haematopoietic reconstitution. These products are listed as medicinal products on the 
Australian Register of Therapeutic Goods (ARTG) following pre-marketing assessments of 
safety and efficacy in clinical trials in a manner broadly similar to the approval processes for 
drugs in the USA and Japan.  
The second category of products are regulated as biologics and include human stem cells, 
tissue-based products, such as skin and bone, genetically modified and in vitro expanded cell-
based products, and combined cell and tissue products. These products are classified 
according to a risk-based framework that is broadly similar that outlined in Japan’s ASRM. 
This framework is detailed in the Australian Regulatory Guidelines for Biologicals, which 
applies oversight measures based on the degree of manipulation or alteration, and the 
intended use (non/homogeneous, autologous/allogeneic) of the CTPs. All CPTs regulated as 
biologics under this framework must be entered onto the ARTG following a pre-market 
approval process, although assessments of safety and efficacy data only apply to products 
classified as higher risk. Manufacturers of these products must also obtain a licence from the 
TGA that demonstrates compliance with principles equivalent to the Australian Code of 
Good Manufacturing Practice (GMP) or Human Blood and Tissues. Very low risk products 
require only a statement of compliance with these standards. At the time of writing, no 
products had been listed in this class.  
Products exempt from both of these categories are not regulated as biological or therapeutic 
goods. Under the Therapeutic Goods (Excluded Goods) Order No. 1 of 2011, these products 
include fresh viable human organs and haematopoietic progenitor cells for the purpose of 
haematopoietic reconstitution, reproductive tissue for use in assisted reproductive therapy, 
and most controversially, CTPs that are collected from a patient who is under the clinical care 
and treatment of a registered medical practitioner, and manufactured by that practitioner, or 
under the professional supervision of that practitioner. In this case, the CTPs must be used in 
the treatment of a “single indication and in a single course of treatment of that patient by the 
same medical practitioner, or by a person or persons under the professional supervision of the 
same medical practitioner” (TGA 2011).  
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The TGA has provided additional guidance of the Exclusion Order, which specifies that the 
CTPs must be for autologous use, that a single medical practitioner must assume 
responsibility for the clinical care of that patient, and where the practitioner is not directly 
involved in the manufacture of the CTP, that there be a “specified relationship with the 
agent/agency that meets the requirements for professional supervision” (TGA 2011).   The 
use of CTPs that are excluded from TGA regulation would thus fall under the jurisdiction of 
the Medical Board of Australia and practitioners must comply with the Good Medical 
Practice: A Code of Conduct for Doctors in Australia. At least three practitioners have been 
disciplined for providing stem cell therapies, with one having their registration suspended for 
three years (McLean, Stewart, and Kerridge 2015). Most recently, the Deputy Coroner in 
New South Wales (2016) recommended an investigation into the professional conduct of 
cosmetic surgeon, Dr Ralph Bright, following the death of a patient who died after 
liposuction that was done to obtain adipocyte-derived ASC for the treatment of her dementia.   
There is little question that the regulatory framework in Australia, particularly the Exclusion 
Order, has encouraged the proliferation of clinics offering autologous ASCs in Australia. 
Unlike the FDA regulations, the Australian framework specifies the techniques and products 
that are excluded from regulation, which implies that everything else would fall under the 
TGA’s jurisdiction unless otherwise stated. This implication means that practitioners can 
assume that a CTP processed with a new technique will fall under the regulations because it 
is not specified as being excluded. The problem with the Exclusion Order, however, is that 
terms such as “single course of treatment”, “professional supervision” and “manufacturing” 
may be mistakenly, or willfully misconstrued, as having different meanings as intended in 
regulatory guidance (McLean, Stewart, and Kerridge 2014). In 2015, the TGA invited public 
submissions on the appropriateness of the Exclusion Order for autologous CTPs. As of 
August 2016, the results of the TGA investigation had not been released and no change had 
been made to the existing regulatory framework. 
Singapore 
Singapore does not have specific legislation to regulate CTPs, although they broadly fall 
within the scope of The Medicines Act (1975, revised 1985). Part 1 Section 3(1) of this Act 
provides laws for the manufacturing, distribution and marketing of medicinal products, 
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defined as “any substance or article (not being an instrument, apparatus or appliance) which 
is manufactured, sold, imported or exported for use wholly or mainly […] for a medicinal 
purpose”. CTPs are not explicitly included in this definition, but nor are biologics, which the 
Health Sciences Authority (HSA) defines in its guidance for registering medicinal products, 
as “products derived from biological systems”, including whole cells or organisms, or parts 
thereof (HSA 2011).   Manufactures of unlicensed products that fall within this definition are 
required to apply for a New Drug Application through the HSA, similar to an IND in the US, 
which is assessed following the submission of clinical documents demonstrating safety and 
efficacy, according to the Medicines (Clinical Trials) Regulations (1978, revised 2000). 
The Medicines Act provides for exceptions to these regulations. According to Part 2 Section 
7(4), restrictions on the sale, supply and manufacturing of medicinal products that are set out 
in Act do not apply to “the preparation, dispensing and assembly of any medicinal product by 
or under the supervision of a practitioner for the purpose of administration to a patient or 
animal under his care”. Thus, as biological medicinal products, the Act would not apply to 
the manufacturing, sale or use of CTPs within hospitals and medical clinics. The Act also 
“does not apply to products categorised and regulated as health products under the Health 
Products Act” (see Part 7 Section 77). Currently though, the Health Products Act (2007) only 
regulates product categories that have been specified in the First Schedule, which is limited to 
medical devices and cosmetic products, and do not include CTPs.3  
The HSA has proposed to add CTPs to the First Schedule and are currently drafting 
regulations to include CTPs as health products. The proposed framework resembles the risk-
based classification system used in Australia and Japan (Ong 2013). If adopted in Singapore, 
it is unclear how CTPs may be used in hospitals as the Health Products Act does not include 
exemptions for products that are manufactured by or under the supervision of medical 
                                                 
3 Medical devices are defined in the Schedule as “any instrument, apparatus, implement, machine, appliance, 
implant, in vitro reagent or calibrator, software, material or other similar or related article” and cosmetic 
products are “any substance or preparation that is intended by its manufacturer to be placed in contact with the 
various external parts of the human body or with the teeth or the mucous membranes of the oral cavity”. Thus, 
while a point-of-care cell processing device may fall within the scope of the Act, the cells processed using this 
technology would not. Health Products Act (2007) Part 1 Section 4(1) 
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practitioners. CTPs that are processed and stored for human transplantation in hospitals and 
medical clinics are covered under the Ministry of Health’s (2003) Guidelines for Healthcare 
Institutions Providing Tissue Banking. Sections 1.1a and b of this guidance include “all 
constituent parts of the human body, including surgical residues” but exclude solid organs, 
placenta, blood and blood products, and reproductive tissues,  as well as tissues that have 
been “processed in such a manner that their functional, structural and biological 
characteristics have been altered”.  These products are classified as biologics, which currently 
fall under the Medicines Act. 
The legal ambiguity may have encouraged a small number of physicians to market stem cells 
in Singapore without prior approval from the HSA. While these physicians had not clearly 
broken any laws, the Singapore Medical Council (SMC) took disciplinary action against three 
practitioners offering stem cells for aesthetic and anti-ageing treatments.4 All three doctors 
were charged with professional misconduct, issued with fines and censured, but not removed 
from the medical register. However, in 2012, the Singapore Court of Appeals overturned the 
SMC’s verdict against one physician on grounds that there were no established or official 
standards for the practice of ‘aesthetic medicine’ at the time of the Discipline Committee’s 
inquiry to substantiate a charge of professional misconduct (High Court of Singapore 2012). 
The SMC has since withdrawn the charges against the physicians in question. No claims have 
surfaced around the use of CTPs for medical indications.   
Legal actions from the SMC may have discouraged other practitioners from offering 
autologous ASCs, although since the appellant Court decision the SMC has not prosecuted 
any other physicians and a Google search in August 2016 revealed at least five clinics offer 
stem-cell based products for aesthetic purposes. Reasons for the lack of clinics offering 
medically- indicated therapies with autologous ASCs in Singapore are unclear since the 
regulations for CTPs are less clear than they are in Australia and the USA. This situation may 
                                                 
4 In 2007, Drs Georgia Lee and Low Chai Ling were censured for offering aesthetic treatments with stem cell 
‘extracts’ without evidence of efficacy (High Court of Singapore 2012); Dr Martin Huang Hsiang Shui in 2009, 
for offering therapies involving the injection of xenogenic (animal) foetal cells into patients for anti-ageing and 
rejuvenation purposes(SMC 2009); and Dr Wong Yoke Meng in 2010, for offering stem cell-based ‘anti-aging’ 
products and therapies that were not medically proven (SMC 2010).  
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change, however, if Singapore adopts the comparable risk-based frameworks to those in 
Australia and Japan.    
United Kingdom 
The UK has also adopted a risk-based approach although it differs slightly from the other 
jurisdictions; partly due to its current status within the European Union. In EU countries, 
CTPs are regulated as ‘advanced therapy medicinal products’ (ATMP) under a national 
framework that integrates the regulations and directives of the European Commission: this 
includes the Tissue Framework Directive (2004/23/EC), the ATMP Regulation (EC No 
1394/2007) and the ATMP Directive (2001/83/EC). According to the ATMP Regulation, a 
centralised authorisation procedure applies to ATMPs that are intended to be marketed within 
the European Union. This procedure requires approval from the European Medicines Agency 
(EMA) following review of the safety and efficacy data. This data is initially reviewed by the 
EMA’s Committee for Advanced Therapies (CAT, 2007), which has the discretion to 
determine the extent and quality of the non-clinical and clinical data to be included in the 
marketing authorisation application as well as conduct of follow-up efficacy, 
pharmacovigilance and risk-management systems. The CAT then makes recommendations to 
the Committee for Medicinal Products for Human Use (CHMP) for final approval.  
The supervisory authority for UK manufacturers or importers of centrally authorised ATMPs 
is the Medicines and Healthcare Products Regulatory Agency (MHRA). The MHRA defines 
CTPs according to the ATMP Directive, which may be classified as a gene therapy product, a 
somatic cell therapy product and/or an engineered tissue product. However, according to Part 
IV of Annex I Part  4 Paragraph 2.2 of ATMP Directive (as amended), the classification of 
somatic cell therapies only includes “cells or tissues that have been subject to substantial 
manipulation so that biological characteristics, physiological functions or structural properties 
relevant for the intended clinical use have been altered”.. Thus, ASCs that are not 
substantially manipulated are excluded from the ATMP Regulations,5 and if used an 
                                                 
5 Non-substantial manipulation includes cutting, grinding, shaping, centrifugation, soaking in antibiotic or 
antimicrobial solutions, sterilization, irradiation, cell separation, concentration or purification, filtering, 
lyophilisation, freezing, cryopreservation and vitrification. EC Regulation No 1394/2007 Annex I 
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autologous graft “within the same surgical procedure and without being subjected to any 
banking process”, would also be excluded from regulation under the Tissue and Cells 
Framework Directive (2004/23/EC Recital 8). Further exemptions are provided under the 
‘Hospital Use’ scheme in Article 3(7) of the ATMP Directive, which allows for the ‘non-
routine’ use of any ATMP for an individual patient. 
Similar to Singapore, the Medicines Act (1968) provides additional exceptions for medicinal 
products that are manufactured under the supervision of a registered medical practitioner. The 
UK framework also provides a ‘specials’ scheme, which allows for the manufacture and 
importation of unlicensed medicinal products. This scheme is enabled under the Medicines 
Act 1968 and the Human Medicines Regulations 2012, although specific guidance is 
currently under review. The purpose of this scheme is to ensure that patients are able to 
access medicines that the MHRA has not approved for marketing. Thus, with permission of 
the MHRA, holders of a specials licence may supply an unapproved CTP to practitioners and 
pharmacies regardless of their intended use, although the procurement and processing of such 
products may still fall under purview of the Tissues and Cells Framework Directive and the 
prescribing physician must conform to accepted ethical standards which place the interests of 
patients before commercial imperatives (Department of Health 2010).  
Outside the formal regulatory framework for CTPs, the conduct of registered practitioners in 
the UK is governed under the practice codes and guidelines of the British General Medical 
Council (GMC). Empowered under the Medical Act 1983, the GMC has the authority to place 
sanctions on practitioners and remove those from the register who’s fitness to practice is 
found to be impaired. In 2010, the GMC (2010) deregistered Dr Robert Trossel following an 
investigation by the Fitness to Practice Panel for unjustifiably administering an allogeneic 
cellular preparation (also found to contain bovine neural cells) to patients affected by 
multiple sclerosis at a clinic in Rotterdam. In its decision, the Panel stated that the 
interventions were based on “anecdotal and aspirational information”, and called his actions 
“unjustifiable” and “exploitative”, and "repeated and serious" breaches of many of the 
"essential tenets" of good medical practice. However, no investigations have been initiated 
against practitioners prescribing autologous ASCs outside of the accepted standard of care. 
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Discussion 
Subtle differences are evident in both the technical language and structure of the regulatory 
instruments that govern experimental and clinical uses of CTPs in the five jurisdictions 
examined. Yet, the general approach is the same: each country is attempting to regulate 
clinical practice so that it is evidence-based. At the same time, the regulations aim to provide 
sufficient clinical freedom so that innovation can be pursued by clinicians and researchers, 
and those interventions that lack the level of evidence necessary for licensing or subsidization 
may still be accessible to patients – particularly those with few other therapeutic options. 
While these are laudable aims, and the approach may support research, it also creates a 
number regulatory weaknesses or loopholes that may be exploited by commercial interests 
and transnational bionetworks.  
Structural Weaknesses in the Regulation of Research and Practice with CTPs 
Each of the countries examined in our analysis attempt to provide a clear evidence-based 
pathway for CTPs that are regulated as medicinal drugs while allowing patients to access 
interventions with autologous ASCs considered as low-risk under the supervision of their 
treating physicians. This general approach is designed to provide the necessary protections 
for research participants while maintaining autonomy for physicians and their patients. To 
support this goal, all five jurisdictions have implemented, or planning to in the case of 
Singapore, a risk-based approach to the regulation of CTPs. This approach gives regulators 
some flexibility in determining the level of oversight and standards of evidence that should 
apply before these products are introduced into clinical settings.  
While autologous ASCs sourced from an individual patient and transplanted back into them 
have lower risks than allogeneic products, little is known about the safety profile of these 
cells outside of autologous haematopoietic progenitor cell transplantation. (Herberts, Kwa, 
and Hermsen 2011). Nevertheless, while details about the level of manipulation and intended 
use of the cells vary slightly across jurisdiction, the general consensus amongst regulators is 
that these products do not pose serious safety threats and are thus subject to relatively 
permissive oversight. Where cells are highly manipulated and there is less certainty about the 
potential risks to patients, regulators impose greater oversight on these products before they 
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are introduced into the market. These CTPs are treated as biological drugs, and sponsors are 
required to obtain an investigational license and demonstrate evidence of safety and efficacy 
in registered clinical trials.  
Yet, even in these instances, there is regulatory flexibility so that patients may have access to 
CTPs that have not been approved for marketing. All jurisdictions have special programs that 
allow patients in exceptional circumstances to access unapproved medicinal drugs. The 
programs differ in name and some of the conditions vary (for example, in the USA, the 
experimental agent must be the subject of an active IND, and in Japan the drug must be 
approved in the exporting country, whereas there are no such restrictions in Australia and the 
UK6); but the basic premise is the same – to ensure that patients can access drugs that might 
save or significantly improve their quality of life on compassionate grounds. This same 
premise applies in principle to autologous ASCs. In a notable case involving the UK and 
Spain, a high risk transplantation of a stem cell engineered trachea was done outside of a 
clinical trial with special permissions from the countries’ regulators (Hollander 2010).  
Further to these exceptional circumstances, all of the jurisdictions (excluding the USA) have 
laws that explicitly allow the manufacture of any medicinal drug, including biologics, under 
the supervision of a registered practitioner within hospitals, by licensed external vendors or 
imported internationally for local uses.  In the USA, the manufacturing of medicinal drugs, 
including CTPs, is controlled where products, or the ingredients that made up those products, 
are shipped across interstate borders. The FDA’s authority over CTPs made with ingredients 
sourced entirely within state borders is unclear (Koustas and Fleder 2011). The United States, 
                                                 
6 See the Expanded Access Program in the US at 
http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/AccesstoInvestigationalDrug s/ucm17609
8.htm; the Named Patients Access program in Japan; the Special Access Scheme in Australia at 
http://www.tga.gov.au/hp/access-sas.htm; the UK Specials Scheme at 
http://www.mhra.gov.uk/Howweregulate/Medicines/Doesmyproductneedalicence/Medicinesthatdonotneedalice
nce/index.htm and the Hospital Exemption Scheme at http://www.mhra.gov.uk/home/groups/es -
policy/documents/publication/con065623.pdf. Singapore does not have a formal program, but the regulator has 
the discretion to apply similar arrangements; see  
http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulat ion/safety_information/product_safety_alert
s/2008/update_on_aprotinin.html  
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therefore, appears to be the most strictly regulated jurisdiction, despite the high number of 
clinics marketing ASCs without FDA approval (Turner and Knoepfler 2016). 
In considering how these discrepant practices occur, it is important to realize that medical 
procedures fall within the practice of medicine, which is regulated under separate governance 
frameworks in all jurisdictions. Thus, the act of prescribing a registered drug or CTP for 
indications that have not been approved (i.e. ‘off-license or ‘off-label’) falls outside of the 
jurisdiction of the regulatory authorities. While practitioners, healthcare institutions or 
manufacturers are not permitted to market or advertise the drug or CTP for any indication 
that has not received pre-market approval, physicians may lawfully prescribe them within the 
discretion of their professional judgment. Where interventions do not fall within the accepted 
standard of care, then practitioners generally need adequate justification and may require 
special permission from an institutions’ clinical practice, clinical governance or ethics board. 
In contrast, if interventions are prescribed as part of a research protocol, then they will 
generally need to be approved by an IRB (expect in the US, where the Common Rule is only 
mandated for research supported with federal funds). However, no permission or oversight is 
required from the authorities that regulate the marketing of medicinal products in any of these 
jurisdictions.  
Other medical procedures that generally fall outside the control of the regulators typically 
include human organ transplants, haematopoietic stem cell transplants using autologous 
grafts or allogeneic tissues obtained from a relative within two degrees of separation, and 
human reproductive tissues that are used for in vitro fertilisation and other artificial 
reproductive technologies. They also generally exclude procedures with autologous ASCs 
that have not been manipulated extensively or combined with other articles and are intended 
for use in functionally compatible tissues. There are, however, important differences in the 
terms used to describe low-risk products as ‘minimally manipulated’ or ‘non-substantially 
manipulated’. The processes that characterize minimal or non-substantial manipulation are 
made explicit in Australia, the UK and Japan, while the USA uses a definition that reflects 
whether the basic characteristics of the cells are altered in the process. This approach 
provides the FDA with greater flexibility, and thus control, over CTPs that fall within its 
jurisdiction. However, because the definition is vague, it is more open to interpretation – and 
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thus challenge – by practitioners who want to offer autologous ASCs without going down the 
IND pathway.   
Conclusions 
Our analysis does not explain why autologous ASCs are being prescribed outside clinical 
trials more often in Australia, Japan and the US, than in Singapore and the UK. While there 
are technical differences and ambiguities in the language and implementation of respective 
regulatory instruments, the general approach in each country is the same – regulating clinical 
practice so that it is evidence-based while still allowing enough freedom for clinicians and 
research to innovate with new interventions and autonomy for patients to access low risk 
CTPs that lack the level of evidence necessary for marketing or subsidization from public and 
private health insurers. Indeed, across all five jurisdictions, regulators and policymakers are 
generally reluctant to interfere in the clinical relationship between doctors and their patients. 
However, while this is historically, culturally and socio-politically acceptable, few would 
agree that physicians should be allowed to prescribe whatever they want without being 
accountable to their patients or to the social and political systems that ultimately pay for the 
provision of their healthcare. In these cases, the professional bodies responsible for the 
oversight of practitioners may be where one should start looking for effective regulation (and 
shortfalls) of CTPs.   
The challenge in implementing these risk-based approaches is that the contexts that create 
scientific research and clinical medicine, and the characteristics of their practices, are 
frequently incompatible. The standards of evidence required to conduct clinical research 
differ greatly from what practitioners need to make clinical decisions. Scientific methodology 
is characterized by uncertainty and researchers design protocols to test hypotheses that have 
inherently uncertain outcomes. The uncertainty that underlies this methodology provides the 
ethical justification for conducting clinical research in the first place. For example, clinical 
equipoise, or the presence of genuine uncertainty (Freedman 1987), provides justification for 
randomization, and trials may be designed to terminate once an acceptable level of certainty 
is reached regarding the question under study. Health professionals, on the other hand, deal 
with evidence and uncertainty differently, and the presence of disagreement within the 
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professional community about treatment options must allow physicians the freedom to 
exercise clinical judgments (Miller and Weijer 2003).  
Regulators attempting to balance the demands of research with professional and patient 
autonomy may thus create a potentially intractable problem. Whereas uncertainty is a key 
driver of the scientific endeavor – and regulations, ethical guidelines and governance 
processes can be designed to minimize harms that may arise from it – regulating clinical 
decisions in the face of uncertainty is, in many ways, much more difficult. However, 
regulators do have power to control unethical and illicit clinical practices; and in this respect 
there are a number of mechanisms that may be used to control the use of autologous ASCs 
outside clinical trials. All five countries have torts laws in place for medical negligence, and 
consumer protection laws that restrict false advertising and the provision of misleading 
information in medical practice. The two countries that have been most successful in limiting 
unethical practices with autologous ASCs – the UK and Singapore – have also activated 
respective medical licensing boards into action against offending practitioners. Even though 
the practitioners in question had been offering allogeneic products, their sanctioning, and 
particularly the deregistration of one, Robert Trossel by the GMC (20102010), would have 
undoubtedly sent a stern warning to other practitioners considering offering unproven 
interventions with any stem cell-based product outside clinical trials.  
While these measures may, at least in part, explain why the prescription of autologous ASCs 
outside clinical trials appears less prevalent in Singapore and the UK than elsewhere, similar 
actions in Australia do not appear to have had any impact on the proliferation of these 
practices. Therefore, additional steps may be necessary to balance the conflicting demands of 
research and practice, and control unethical practices with stem cells. For a start, clearer 
guidance is needed for clinicians who want to prescribe low-risk interventions with 
autologous ASCs responsibly and access higher-risk CTPs before they have been approved 
for marketing. Special access schemes are already in place for these purposes, however, to 
whom these provisions may apply and who should have access to specific cell populations 
needs to be clarified. Further clarification is also needed on who should pay for interventions 
that have not been approved for marketing or demonstrated as safe and effective as costs for 
such treatments are generally not reimbursable under public or private health insurance 
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providers. The types of skills and expertise required for the isolation and processing of cell 
populations, as well as the disease being targeted for treatment, are issues that should warrant 
further discussion.  
Beyond professional guidelines, greater consistency and less ambiguity in regulatory 
instruments across jurisdictions is necessary because even though they provide regulators 
with a degree of discretion, the vagaries and inconsistencies are also open to willful 
misinterpretation and exploitation by unscrupulous operators. Relevant authorities should 
also activate existing laws and regulations that protect consumers from false advertising and 
the provision of misleading information in medical practice. It is crucial that the wholesale 
marketing of such interventions without sufficient evidence should be prosecuted under the 
relevant consumer protection laws and offending practitioners sanctioned by the responsible 
medical authority. For clinical practice cannot be regulated in the same way as research if the 
goal is to ensure that patients have access to novel interventions where efficacy is uncertain 
and that innovation can occur within clinical contexts.  
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